

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES


Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



Amelt G

SEQUENCE LISTING

<110> SUMITOMO PHARMACEUTICALS COMPANY, LIMITED
SAITO, Izumi
SAITO, Yumi

<120> DNA Containing Variant FRT Sequence

<130> 1422-0527P

<140> US 10/089,380

<141> 2002-03-29

<150> JP 11-280210

<151> 1999-09-30

<150> JP 11-346727

<151> 1999-12-06

<150> PCT/JP00/06686

<151> 2000-09-28

<160> 36

<210> 1

<211> 34

<212> DNA

<213> Saccharomyces cerevisiae

<400> 1

gaagttccta tactttctag agaataggaa cttc

34

<210> 2

<211> 34

<212> DNA

<213> Saccharomyces cerevisiae

<400> 2

gaagttccta tactctctgg agaataggaa cttc

34

<210> 3

<211> 34

<212> DNA

<213> Saccharomyces cerevisiae

<400> 3

gaagttccta tactctccag agaataggaa cttc

34

<210> 4

<211> 34

<212> DNA

<213> Saccharomyces cerevisiae

<400> 4

gaagttccta tactatcttg agaataggaa cttc

34

<210> 5

<211> 34
 <212> DNA
 <213> Saccharomyces cerevisiae

<400> 5
 gaagttccta tactttctgg agaataggaa cttc 34

<210> 6
 <211> 34
 <212> DNA
 <213> Saccharomyces cerevisiae

<400> 6
 gaagttccta tactatttga agaataggaa cttc 34

<210> 7
 <211> 34
 <212> DNA
 <213> Saccharomyces cerevisiae

<400> 7
 gaagttccta taccttgtga agaataggaa cttc 34

<210> 8
 <211> 34
 <212> DNA
 <213> Saccharomyces cerevisiae

<400> 8
 gaagttccta tactatctac agaataggaa cttc 34

<210> 9
 <211> 34
 <212> DNA
 <213> Saccharomyces cerevisiae

<400> 9
 gaagttccta tactgtctat agaataggaa cttc 34

<210> 10
 <211> 27
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> The oligonucleotide is synthesized DNA adaptor.

<400> 10
 agcttctgca gcagaccgtg catcatg 27

<210> 11
 <211> 19
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> The oligonucleotide is synthesized DNA adaptor.

<400> 11
atgcacggtc tgctgcaga 19

<210> 12
<211> 52
<212> DNA
<213> Artificial Sequence

<220>
<223> Designed oligonucleotide based on wild type FRT sequence.

<400> 12
tcgaggacgt cgaagttcct atactttcta gagaatagga acttctccgg aa 52

<210> 13
<211> 52
<212> DNA
<213> Artificial Sequence

<220>
<223> Designed oligonucleotide based on wild type FRT sequence.

<400> 13
ctagttccgg agaagttcct attctctaga aagtatagga acttcgacgt cc 52

<210> 14
<211> 52
<212> DNA
<213> Artificial Sequence

<220>
<223> Designed oligonucleotide based on mutant FRT sequence.

<400> 14
tcgaggacgt cgaagttcct atactatcta gagaatagga acttctccgg aa 52

<210> 15
<211> 52
<212> DNA
<213> Artificial Sequence

<220>
<223> Designed oligonucleotide based on mutant FRT sequence.

<400> 15
tcgaggacgt cgaagttcct atactttctg gagaatagga acttctccgg aa 52

<210> 16
<211> 52
<212> DNA
<213> Artificial Sequence

<220>
<223> Designed oligonucleotide based on mutant FRT sequence.

<400> 16

tcgaggacgt cgaagttcct atactttcta cagaatagga acttctccgg aa

52

<210> 17

<211> 52

<212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide based on mutant FRT sequence.

<400> 17

tcgaggacgt cgaagttcct atactatttg aagaatagga acttctccgg aa

52

<210> 18

<211> 52

<212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide based on mutant FRT sequence.

<400> 18

tcgaggacgt cgaagttcct atactctctg gagaatagga acttctccgg aa

52

<210> 19

<211> 52

<212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide based on mutant FRT sequence.

<400> 19

tcgaggacgt cgaagttcct atactatcta cagaatagga acttctccgg aa

52

<210> 20

<211> 52

<212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide based on mutant FRT sequence.

<400> 20

tcgaggacgt cgaagttcct atactctcca gagaatagga acttctccgg aa

52

<210> 21

<211> 52

<212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide based on mutant FRT sequence.

<400> 21

tcgaggacgt cgaagttcct atactatctt gagaatagga acttctccgg aa

52

<210> 22
<211> 52
<212> DNA
<213> Artificial Sequence

<220>
<223> Designed oligonucleotide based on mutant FRT sequence.

<400> 22
tcgaggacgt cgaagttcct atactgtcta tagaatagga acttctccgg aa 52

<210> 23
<211> 52
<212> DNA
<213> Artificial Sequence

<220>
<223> Designed oligonucleotide based on mutant FRT sequence.

<400> 23
ctagttccgg agaagttcct attctctaga tagtatagga acttcgacgt cc 52

<210> 24
<211> 52
<212> DNA
<213> Artificial Sequence

<220>
<223> Designed oligonucleotide based on mutant FRT sequence.

<400> 24
ctagttccgg agaagttcct attctccaga aagtatagga acttcgacgt cc 52

<210> 25
<211> 52
<212> DNA
<213> Artificial Sequence

<220>
<223> Designed oligonucleotide based on mutant FRT sequence.

<400> 25
ctagttccgg agaagttcct attctgtaga aagtatagga acttcgacgt cc 52

<210> 26
<211> 52
<212> DNA
<213> Artificial Sequence

<220>
<223> Designed oligonucleotide based on mutant FRT sequence.

<400> 26
ctagttccgg agaagttcct attcttcaaa tagtatagga acttcgacgt cc 52

<210> 27
<211> 52

<212> DNA
<213> Artificial Sequence

<220>
<223> Designed oligonucleotide based on mutant FRT sequence.

<400> 27
ctagttccgg agaagttcct attctccaga gagtatagga acttcgacgt cc 52

<210> 28
<211> 52
<212> DNA
<213> Artificial Sequence

<220>
<223> Designed oligonucleotide based on mutant FRT sequence.

<400> 28
ctagttccgg agaagttcct attctgtaga tagtatagga acttcgacgt cc 52

<210> 29
<211> 52
<212> DNA
<213> Artificial Sequence

<220>
<223> Designed oligonucleotide based on mutant FRT sequence.

<400> 29
ctagttccgg agaagttcct attctctgga gagtatagga acttcgacgt cc 52

<210> 30
<211> 52
<212> DNA
<213> Artificial Sequence

<220>
<223> Designed oligonucleotide based on mutant FRT sequence.

<400> 30
ctagttccgg agaagttcct attctcaaga tagtatagga acttcgacgt cc 52

<210> 31
<211> 52
<212> DNA
<213> Artificial Sequence

<220>
<223> Designed oligonucleotide based on mutant FRT sequence.

<400> 31
ctagttccgg agaagttcct attctataga cagtatagga acttcgacgt cc 52

<210> 32
<211> 34
<212> DNA
<213> Artificial Sequence

<220>

<223> Designed oligonucleotide based on mutant FRT sequence.

<400> 32

gaagttccta tactttctac agaataggaa cttc

34

<210> 33

<211> 54

<212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide based on FLP recognition sequence.

<400> 33

aaattccgga gaagttccta ttctctagaa agtataggaa cttcgacgtc attt

54

<210> 34

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide as polylinker based on recognition sequences of SmaI, EcoRI, ScaI, KpnI and SmaI, in this order.

<400> 34

aaattgaatt cgagctcggt acccggg

27

<210> 35

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide as linker based on sequence encoding BglII recognition sequence, two stop codons, and XhoI recognition sequence.

<400> 35

gatcttacta gtaggatc

18

<210> 36

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide as linker based on sequence encoding BglII recognition sequence, two stop codons, and XhoI recognition sequence.

<400> 36

tcgagatcct actagtaa

18